Acquired by Inscripta in 2018- Assisting with late stage development - Contract manufacturing services- Custom enzyme production

Illumina, Inc. 2006 – 2017Director of Engineering 2015 - 2017Assoc. Dir. Engineering 2012 - 2015Sr. Engineering Manager 2010 - 2012Engineering Manager 2009 - 2010Engineering Supervisor 2008-2009Sr. Engineer 2007 - 2008Engineer II 2006 – 2007Starting in 2010, built from the ground up and managed a technical team of >65 engineers and scientists directly responsible for the following:1. process development, analytical method development, analytical product characterization, analytical method validation, and technology transfer of all sequencing reagent consumables 2. from 2009 to present that oversaw a SKU portfolio expansion of >800% from 2009 to present3. market segments that range from RUO through FDA regulated (PMA submission) including the first NGS platform cleared by the FDA, the first NGS cystic fibrosis NGS workflow cleared by the FDA, and multiple CE-IVD cleared products4. assisted in product development through ownership of analytical characterization of library prep, clustering, and SBS reagents, intermediates, and raw materials5. ownership of re-development of reagents from field related complaints back through operations and re-launch6. scale-up over 5 years of reagent manufacturing by > 285%, scale up of oligo manufacturing by >175%, and dye labeled nucleotide manufacturing by >350%. Expat from 2008 – 2009 and lead that executed startup of a Singapore manufacturing plant responsible for in excess of $60M over 3 years and $650M in revenue over 10 yearsOwned a cost savings roadmap that have added > $65M in realized savings over 4 yearsExpat in 2010 that oversaw the transfer of dye-labeled nucleotide manufacturing from UK to USSuccessful tech transfer for CE/IVD and 510K submission, approval, and successful FDA audit for first Next Generation Sequencing (NGS) approved sequencer and consumablesManaged a capital budget that on average exceeded $10M / year

Key Accomplishments• Supported manufacturing and scale-up of micro-fluidics sandwich assay medical devices that supported >$200M / year• Supported characterization and root cause analysis of field complaints for micro-fluidics sandwich assay medical devices

• Synthesized oligonucleotides on MilliPore 8800 and Amersham ACTA equipment on a 0.5 – 20g scale for antisense drug studies. • Characterized oligonucleotides via LC, LC-MS, CE, and UV-Spectroscopy.• Developed new methods and SOPs for analytical analysis of oligonucleotides on Waters LC systems.• Detritilitated and Purified oligonucleotides via Waters HPLC.• Troubleshot and performed preventative maintenance on Synthesizers, CE, and HPLC systems. • Management of materials and computerized database to assist ongoing research projects.• Streamlined final quality control process and assisted in testing new synthesis processes.